ClinicalTrials.gg

Program

Rituximab

Also written as “rituximab”, “rituximab [MabThera/Rituxan]” and “Rituximab SC”.

Its studies are mostly in Arthritis, Rheumatoid · Lymphoma, Non-Hodgkin · Lymphoma, Large B-Cell, Diffuse · Lymphoma, Follicular · Leukemia, Lymphocytic, Chronic, B-Cell, led by 20 companies.

Furthest: phase 4, since Jan 18, 2007124 company-led studies, 6 open or runningNext primary completion: Oct 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Hoffmann-La Roche781 open or runningphase 4since Jan 18, 2007Apr 1, 2003none ahead
SymBio Pharmaceuticals50 open or runningphase 3since Dec 10, 2017Nov 18, 2008none ahead
AbbVie40 open or runningphase 3since Jun 9, 2014Apr 20, 2012none ahead
AstraZeneca42 open or runningphase 4since Aug 23, 2023Apr 8, 2016Oct 31, 2028phase 2 · NCT05951959
Biogen40 open or runningphase 4since Aug 23, 2004Mar 31, 2003none ahead
Takeda40 open or runningphase 3since Apr 7, 2006Jun 11, 2004none ahead
Biocad30 open or runningphase 3since Oct 3, 2012Oct 3, 2012none ahead
Celltrion30 open or runningphase 1since Feb 8, 2012Feb 8, 2012none ahead
favrille30 open or runningphase 3since Aug 4, 2004Aug 4, 2004none ahead
GlaxoSmithKline20 open or runningphase 3since Oct 13, 2017Dec 14, 2015none ahead
ImmunityBio22 open or runningphase 1since Oct 19, 2022Oct 19, 2022Oct 2027phase 1 · NCT06334991
mabion-sa20 open or runningphase 3since Jun 9, 2015Jun 9, 2015none ahead
Merck20 open or runningphase 1since May 18, 2011May 18, 2011none ahead
Sarah Cannon Research Institute20 open or runningphase 2since Nov 7, 2005Nov 7, 2005none ahead
Amgen10 open or runningphase 2since Jul 5, 2000Jul 5, 2000none ahead
Bayer10 open or runningphase 2since Jul 8, 2004Jul 8, 2004none ahead
mabscale-llc11 open or runningphase 1since Dec 7, 2023Dec 7, 2023none ahead
pharmatech10 open or runningphase 2since Jan 26, 2009Jan 26, 2009none ahead
probiomed-s-a-de-c-v10 open or runningphase 3since Jan 8, 2011Jan 8, 2011none ahead
Sinocelltech Group10 open or runningphase 1since Jul 30, 2014Jul 30, 2014none ahead

Also a collaborator on its studies: icon-clinical-research, Johnson & Johnson, Bristol-Myers Squibb, Merck KGaA, Darmstadt, Germany, UCB, Eli Lilly, Teva Pharmaceutical Industries, roche-pharma-ag and chiron-corporation.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 46 studies since Jan 7, 2011.

  1. Oct 13, 2017Phase 3 study in Lupus Erythematosus, SystemicGlaxoSmithKline · NCT03312907 · 292 enrolled · United States, Argentina, Brazil and more
  2. Dec 10, 2017Phase 3 study in Lymphoma, Large B-Cell, DiffuseSymBio Pharmaceuticals · NCT03372837 · 40 enrolled · Japan
  3. Mar 6, 2019Phase 2 study in LymphomaSymBio Pharmaceuticals · NCT03900377 · 37 enrolled · Japan
  4. Jul 22, 2019Phase 1 study in Multiple MyelomaHoffmann-La Roche · NCT04045028 · 41 enrolled · United States, Korea, Republic of
  5. Nov 25, 2020Phase 2 study in Lymphoma, Large B-Cell, DiffuseHoffmann-La Roche · NCT04660799 · 50 enrolled · China
  6. Jan 13, 2021Phase 3 study in RecurrenceHoffmann-La Roche · NCT04712097 · 478 enrolled · United States, Australia, Brazil and more
  7. Mar 8, 2021Phase 1 study in Lymphoma, Large B-Cell, DiffuseHoffmann-La Roche · NCT04790903 · 50 enrolled · United States, France, Italy and more
  8. May 3, 2022Phase 1 study in Lymphoma, Large B-Cell, DiffuseHoffmann-La Roche · NCT05364424 · 43 enrolled · United States
  9. Oct 19, 2022ImmunityBio's first study: phase 1 study in RecurrenceNew to ImmunityBioImmunityBio · NCT05618925 · 20 planned · United States
  10. Jun 5, 2023Phase 2 study in Lymphoma, Mantle-CellAstraZeneca · NCT05951959 · 108 enrolled · United States, Australia, Brazil and more
  11. Jul 11, 2023Phase 2 study in Lymphoma, Large B-Cell, DiffuseAstraZeneca · NCT05952024 · 80 planned · United States, Brazil, Puerto Rico and more
  12. Aug 23, 2023Phase 4 study in HypophosphatasiaAstraZeneca · NCT06015750
  13. Dec 7, 2023mabscale-llc's first study: phase 1 study in Arthritis, RheumatoidNew to mabscale-llcmabscale-llc · NCT06175338 · 208 enrolled · Russian Federation
  14. Mar 5, 2024Phase 1 study in Non-Hodgkin Lymphoma Refractory/ RelapsedImmunityBio · NCT06334991 · 20 enrolled · South Africa

Ahead

  1. Oct 2027Primary completion: phase 1 study in Non-Hodgkin Lymphoma Refractory/ RelapsedImmunityBio · NCT06334991
  2. Oct 31, 2028Primary completion: phase 2 study in Lymphoma, Mantle-CellAstraZeneca · NCT05951959
  3. Apr 22, 2029Primary completion: phase 2 study in Lymphoma, Large B-Cell, DiffuseAstraZeneca · NCT05952024

TargetBeta

MS4A1 →read by rule
“A recombinant chimeric murine/human antibody directed against the CD20 antigen, a hydrophobic transmembrane protein located on normal pre-B and mature B lymphocytes”NCIt, by rule
“B-lymphocyte antigen CD20 binding agent”ChEMBL 37, by rule

Other programs on MS4A1

ProgramCompanyFurthest phaseStudies
ocrelizumabruleHoffmann-La Rochephase 442
obinutuzumabruleHoffmann-La Rochephase 442
ublituximabruleTG Therapeuticsphase 323
mosunetuzumabruleHoffmann-La Rochephase 314
glofitamabruleHoffmann-La Rochephase 313
epcoritamabruleGenmabphase 313
Anti-CD20 Monoclonal Antibody MIL62rulebeijing-mabworks-biotech-co-ltdphase 310
odronextamabruleRegeneron Pharmaceuticalsphase 38
TQB2825Sino Biopharmaceuticalphase 35
zuberitamabrulebioray-pharmaceutical-co-ltdphase 33
rondecabtagene autoleucelrulelyell-immunopharma-incphase 32
zamtocabtagene autoleucelrulemiltenyi-biomedicine-gmbhphase 28

Studies

The newest 60 of 124 led by companies developing it. Each opens its study page. Every study on its drug page →

StudyPhaseStatusLed byPrimary completionSize
NCT06334991Non-Hodgkin Lymphoma Refractory/ Relapsed · South Africa1Active, not recruitingImmunityBioOct 202720
NCT06175338Arthritis, Rheumatoid · Russian Federation1Active, not recruitingmabscale-llcNov 2024208
NCT06015750Hypophosphatasia4WithdrawnAstraZenecaMar 13, 20300
NCT05952024Lymphoma, Large B-Cell, Diffuse · United States, Brazil, Puerto Rico and more2RecruitingAstraZenecaApr 22, 202980
NCT05951959Lymphoma, Mantle-Cell · United States, Australia, Brazil and more2Active, not recruitingAstraZenecaOct 31, 2028108
NCT05618925Recurrence · United States1RecruitingImmunityBioMay 15, 202620
NCT05364424Lymphoma, Large B-Cell, Diffuse · United States1CompletedHoffmann-La RocheOct 15, 202543
NCT04790903Lymphoma, Large B-Cell, Diffuse · United States, France, Italy and more1TerminatedHoffmann-La RocheMay 21, 202450
NCT04712097Recurrence · United States, Australia, Brazil and more3Active, not recruitingHoffmann-La RocheJun 3, 2026478
NCT04660799Lymphoma, Large B-Cell, Diffuse · China2CompletedHoffmann-La RocheMay 23, 202250
NCT04045028Multiple Myeloma · United States, Korea, Republic of1TerminatedHoffmann-La RocheMar 28, 202341
NCT03900377Lymphoma · Japan2CompletedSymBio PharmaceuticalsSep 9, 202037
NCT03372837Lymphoma, Large B-Cell, Diffuse · Japan3CompletedSymBio PharmaceuticalsDec 31, 201940
NCT03312907Lupus Erythematosus, Systemic · United States, Argentina, Brazil and more3CompletedGlaxoSmithKlineMay 29, 2020292
NCT02735876Lymphoma, Mantle-Cell3WithdrawnAstraZenecaJun 20200
NCT02744196Arthritis, Rheumatoid3CompletedBiocadFeb 2017159
NCT02693210Arthritis, Rheumatoid · Australia, Belgium, Canada and more2CompletedHoffmann-La RocheAug 2002161
NCT02631538Sjogren's Syndrome · Argentina, Canada, France and more2CompletedGlaxoSmithKlineJun 23, 202086
NCT02617485Lymphoma, Large B-Cell, Diffuse · Bosnia and Herzegovina, Croatia, Georgia and more3Completedmabion-saAug 2017143
NCT02600897Recurrence · United States, Spain, United Kingdom2CompletedHoffmann-La RocheDec 15, 2021114
NCT02569996Lymphoma, Follicular · Hungary3CompletedHoffmann-La RocheAug 2013124
NCT02533401Leukemia, Lymphocytic, Chronic, B-Cell · Argentina, Venezuela2CompletedHoffmann-La RocheDec 201434
NCT02468791Arthritis, Rheumatoid · Bosnia and Herzegovina, Georgia, Poland and more3Completedmabion-saMay 2017709
NCT02406092Lymphoma, Non-Hodgkin · Algeria, Morocco, Tunisia3CompletedHoffmann-La RocheJun 30, 2021139
NCT02383589Pemphigus · United States, Argentina, Australia and more3CompletedHoffmann-La RocheNov 28, 2018135
NCT02257567Lymphoma · United States, Australia, Canada and more2CompletedHoffmann-La RocheOct 21, 2021331
NCT02206308Lymphoma, B-Cell1CompletedSinocelltech GroupJul 201315
NCT02165397Waldenstrom Macroglobulinemia · United States, Australia, Canada and more3CompletedAbbVieNov 7, 2019181
NCT02115997Granulomatosis with Polyangiitis · India4CompletedHoffmann-La RocheJun 7, 202230
NCT02097745Arthritis, Rheumatoid · United States, Belgium, Canada and more3CompletedHoffmann-La RocheJun 2013341
NCT02093026Arthritis, Rheumatoid · United States, Australia, Belgium and more2CompletedHoffmann-La RocheDec 2012465
NCT02079532Arthritis, Rheumatoid · Germany3CompletedHoffmann-La RocheNov 2010302
NCT02077166Lymphoma, Large B-Cell, Diffuse · United States, Belgium, Germany and more2CompletedAbbVieDec 17, 2020138
NCT02055820Lymphoma, Non-Hodgkin · United States, Australia, Austria and more2CompletedHoffmann-La RocheJun 28, 2017267
NCT02006706Arthritis, Rheumatoid · Serbia3CompletedHoffmann-La RocheNov 23, 200715
NCT02013817Leukemia, Lymphocytic, Chronic, B-Cell · Austria2CompletedHoffmann-La RocheSep 24, 201243
NCT01998893Lymphoma, Non-Hodgkin · Germany2CompletedHoffmann-La RocheFeb 200838
NCT01987505Lymphoma, Non-Hodgkin · Spain3CompletedHoffmann-La RocheApr 11, 2017140
NCT01980654Lymphoma, Follicular · United States2CompletedAbbVieNov 201780
NCT01889069Lymphoma · Italy3CompletedHoffmann-La RocheMay 28, 2019159
NCT01873443Arthritis, Rheumatoid · Korea, Republic of1CompletedCelltrionOct 201487
NCT01759030Arthritis, Rheumatoid · Belarus, India, Russian Federation and more3CompletedBiocadJul 2015181
NCT01750697Granulomatosis with Polyangiitis · United States, Canada, France and more2CompletedHoffmann-La RocheMay 10, 201825
NCT01724021Lymphoma, Large B-Cell, Diffuse · Argentina, Australia, Austria and more3CompletedHoffmann-La RocheJan 2015743
NCT01718691Low-grade B Cell Non-Hodgkin's Lymphoma · Japan2CompletedSymBio PharmaceuticalsNov 201370
NCT01701232Lymphoma, Follicular · Colombia, India, Russian Federation and more3CompletedBiocadJan 2017174
NCT01671904Leukemia, Lymphocytic, Chronic, B-Cell · United States, France, Germany1CompletedHoffmann-La RocheAug 17, 201884
NCT01649856Lymphoma, Large B-Cell, Diffuse · Algeria, Argentina, Belgium and more3CompletedHoffmann-La RocheOct 21, 2014572
NCT01594229Lymphoma, Non-Hodgkin · United States1CompletedAbbVieJul 14, 202060
NCT01534949Lymphoma, Large B-Cell, Diffuse · Korea, Republic of1TerminatedCelltrionFeb 20131
NCT01534884Arthritis, Rheumatoid · Korea, Republic of1CompletedCelltrionAug 2013154
NCT01461928Lymphoma, Non-Hodgkin · Albania, Argentina, Austria and more3CompletedHoffmann-La RocheJun 2, 2018692
NCT01397825Lymphoma, Large B-Cell, Diffuse · United States, Italy, Spain and more2CompletedTakedaFeb 5, 201545
NCT01390441Arthritis, Rheumatoid1TerminatedMerckApr 2014100
NCT01392716Lymphoma, Non-Hodgkin · France2CompletedHoffmann-La RocheFeb 200648
NCT01388959Lymphoma, Non-Hodgkin · France2CompletedHoffmann-La RocheApr 200440
NCT01382940Arthritis, Rheumatoid · United States4CompletedHoffmann-La RocheJan 6, 2013351
NCT01370694Lymphoma, Follicular1TerminatedMerckDec 1, 20147
NCT01277172Lymphoma, Large B-Cell, Diffuse · Mexico3UNKNOWNprobiomed-s-a-de-c-vSep 201154
NCT01272908Arthritis, Rheumatoid · Canada, Sweden3CompletedHoffmann-La RocheMar 12, 2009120

How it is read

Names in the registry

  • “Rituximab”, 104 entries
  • “rituximab”, 34 entries
  • “rituximab [MabThera/Rituxan]”, 23 entries
  • “Rituximab SC”, 2 entries
  • “MK-8808”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.